# Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

Study · id `cardio:ct-nct05136664` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05136664](<https://clinicaltrials.gov/study/NCT05136664>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05136664

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 262 participants.

## Technical summary

Registry record NCT05136664. Randomized; single masking; primary purpose treatment. Start 2022-02-10 (actual); primary completion 2025-11-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 262 participants (enrolled count; ClinicalTrials.gov record NCT05136664, source copy `cardio:ctgov-nct05136664-2026-04-13`, retrieved 2026-10-26)
- Started: 2022-02-10 (actual) (ClinicalTrials.gov record NCT05136664, source copy `cardio:ctgov-nct05136664-2026-04-13`, retrieved 2026-10-26)
- Primary completion: 2025-11-18 (actual) (ClinicalTrials.gov record NCT05136664, source copy `cardio:ctgov-nct05136664-2026-04-13`, retrieved 2026-10-26)
- Completion: 2025-11-18 (actual) (ClinicalTrials.gov record NCT05136664, source copy `cardio:ctgov-nct05136664-2026-04-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05136664, source copy `cardio:ctgov-nct05136664-2026-04-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05136664-2026-04-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
- Acronym: Patiromer JADE
- Condition: Hyperkalemia
- Condition: Renal Insufficiency, Chronic
- Intervention (Drug): Patiromer Powder for Oral Suspension (Part A)
- Intervention (Drug): Placebo (Part B)
- Intervention (Drug): Patiromer Powder for Orals Suspension (Part B)
- Lead sponsor: Vifor Fresenius Medical Care Renal Pharma
- Lead sponsor class: INDUSTRY
- Collaborator: Tigermed Consulting Co., Ltd
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as a collaborator: Tigermed Consulting Co., Ltd (`cardio:org-tigermed-consulting-co-ltd`)

## Provenance

Content hash: e7b5b2ccbf7a7bcbe6e24de3e29ac5409577e2747ae06f01c403891b728a74f1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
